Corcept Therapeutics Statistics

Total Valuation

LON:0I3Q has a market cap or net worth of GBP 5.59 billion. The enterprise value is 5.15 billion.

Market Cap	5.59B
Enterprise Value	5.15B

Important Dates

The next estimated earnings date is Friday, May 2, 2025.

Earnings Date	May 2, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.56%
Shares Change (QoQ)	+4.16%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	86.95M

Valuation Ratios

The trailing PE ratio is 50.09.

PE Ratio	50.09
Forward PE	n/a
PS Ratio	10.37
PB Ratio	10.30
P/TBV Ratio	10.30
P/FCF Ratio	35.73
P/OCF Ratio	35.34
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 48.95, with an EV/FCF ratio of 32.88.

EV / Earnings	46.10
EV / Sales	10.21
EV / EBITDA	48.95
EV / EBIT	50.30
EV / FCF	32.88

Financial Position

The company has a current ratio of 3.35, with a Debt / Equity ratio of 0.01.

Current Ratio	3.35
Quick Ratio	3.11
Debt / Equity	0.01
Debt / EBITDA	0.05
Debt / FCF	0.04
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 23.81% and return on invested capital (ROIC) is 14.34%.

Return on Equity (ROE)	23.81%
Return on Assets (ROA)	11.71%
Return on Invested Capital (ROIC)	14.34%
Return on Capital Employed (ROCE)	19.57%
Revenue Per Employee	1.08M
Profits Per Employee	223,229
Employee Count	500
Asset Turnover	0.92
Inventory Turnover	1.08

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +211.15% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+211.15%
50-Day Moving Average	65.33
200-Day Moving Average	51.94
Relative Strength Index (RSI)	53.01
Average Volume (20 Days)	4,154

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	7.70

Income Statement

In the last 12 months, LON:0I3Q had revenue of GBP 539.20 million and earned 111.61 million in profits. Earnings per share was 0.98.

Revenue	539.20M
Gross Profit	530.51M
Operating Income	109.39M
Pretax Income	129.00M
Net Income	111.61M
EBITDA	110.03M
EBIT	109.39M
Earnings Per Share (EPS)	0.98

Full Income Statement

Balance Sheet

The company has 306.20 million in cash and 5.54 million in debt, giving a net cash position of 476.25 million.

Cash & Cash Equivalents	306.20M
Total Debt	5.54M
Net Cash	476.25M
Net Cash Per Share	n/a
Equity (Book Value)	542.84M
Book Value Per Share	5.16
Working Capital	264.26M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 158.21 million and capital expenditures -1.73 million, giving a free cash flow of 156.48 million.

Operating Cash Flow	158.21M
Capital Expenditures	-1.73M
Free Cash Flow	156.48M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 98.39%, with operating and profit margins of 20.29% and 20.92%.

Gross Margin	98.39%
Operating Margin	20.29%
Pretax Margin	23.92%
Profit Margin	20.92%
EBITDA Margin	20.41%
EBIT Margin	20.29%
FCF Margin	29.02%

Dividends & Yields

LON:0I3Q does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.56%
Shareholder Yield	-1.56%
Earnings Yield	2.00%
FCF Yield	2.80%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

LON:0I3Q has an Altman Z-Score of 16.28.

Altman Z-Score	16.28
Piotroski F-Score	n/a